Skip to main content

Table. 3 Weight evolution

From: Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV

A. TDF/TDF group, Mean [95% CI]

 

N

2016

2018

Evolution

2018–2016

p-value

Weight (kg)

30

74.9 [69.3;80.5]

74.3 [68.2;80.4]

− 0.63 [− 2.1;0.81]

0.38

B. TDF/TAF group, Mean [95%CI]

 

N

Before

(on TDF)

After

(on TAF)

Evolution

After–Before

p-value

Weight (kg)

83

78.7 [75.2;82.2]

79.6 [76.3;82.9]

0.94 [− 0.55;2.4]

0.21